The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody ...

Macrophage cells are the immune system's frontline soldiers, early on the scene to protect the body from foreign invaders.

More than 200 viruses can infect and cause disease in humans; most of us will be infected by several over the course of a lifetime. Does an encounter with one virus influence how your immune ...

Hematologic malignancies, including leukemia, lymphoma, and myeloma, present considerable clinical challenges, driven in part by their unique tumor microenvironments and the ability of cancer cells to ...

Richard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both immune oncology and inflammatory diseases. In healthy tissues ...

Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S.Seasoned Team to Drive Forward ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

Separate lines of evidence implicate the cytokine macrophage migration inhibitory factor (MIF) in RA, SLE, and atherosclerosis. Several reports have revealed definitive in vivo evidence of the ...

Eicosapentaenoic acid (EPA) prevents diabetic cardiomyopathy (DC) by promoting the transition of macrophages from M1 to Mox ...

Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...

This study demonstrates that global or adipose tissue-specific knockout of CIDEC/FSP27 significantly reduces AAA incidence ...